How do conventional markers of lipid disorders compare with apolipoproteins?

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 65, Issue 1, 2005, Pages 33-44

  Estonius, M ^a   Kallner, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CHD; Coronary heart disease; Cost analysis; Diagnostic sensitivity; Diagnostic specificity; Risk assessment; ROC analysis; Scattergrams

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; GENDER; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ROC CURVE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS; BIOLOGICAL MARKERS; CHILD; CORONARY DISEASE; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; ROC CURVE; SEX CHARACTERISTICS;

EID: 14044269490     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510510013497     Document Type: Article

References (19)

1. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:148-56.
2. Nauck M, Winkler K, März W, Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein[a] by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995;41:1761-7.
3. Executive summary of the 3rd Report of the National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). J Am Med Ass 2001;285:2486-97 [http://nhlbi.nih.gov [visited 04-06-01].
4. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
5. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: the twin Achilles' heels of the Friedewald formula. Clin Biochem 2003;36:499-504.
6. Scharnagl H, Nauck M, Wieland H, März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001;39:426-31.
7. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of CHD and targets for lipid-modifying therapy. J Intern Med 2004;255:188-205.
8. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002;106:2526-9.
9. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777-80.
10. Yusuf S, Hawken S, Öunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
11. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. Part IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994;40:586-92.
12. Kragten J. Calculating standard deviations and confidence intervals with a universally applicable spreadsheet technique. Analyst 1994;119:2161-6.
13. Nauck M, Warnick GR, Rifat N. Method for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002;48:236-54.
14. Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID Jr. Measurement of low-density-lipoproteins cholesterol in serum: a status report. Clin Chem 1992;38:150-60.
15. Jungner I, Marcovina S, Walldius G, Holme I, Kolar W, Steiner E. Apolipoprotein B and A-I values on 147,576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry first international reference material. Clin Chem 1998;44:1641-9.
16. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High Apolipoprotein B, low Apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
17. Franzini C, Valente C, Luraschi. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B: relationships among the different measurements. Scand J Clin Lab Invest 2004;64:703-8.
18. Sniderman Ad, Scantlebury T, Cianfione K. Hypertriglyceridemic hyper Apo B: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001;135:447-59.
19. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004;35:2248-52.